Forget Veganuary and Dry January – there's a new health trend taking supermarkets by storm: 'Jab-uary'! This year, grocery stores across the UK are rolling out specialized food ranges catering to individuals using weight-loss drugs. But is this a genuine response to consumer needs, or just a clever marketing ploy? Let's dive in.
Major retailers like Marks & Spencer, Morrisons, Asda, Ocado, and the Co-op are all vying for the attention of shoppers using weight-loss injections, known as GLP-1 agonists, such as Wegovy and Mounjaro.
Ocado has even launched a virtual "weight management" aisle, featuring a curated selection of "GLP-1-friendly products." These range from small portions of steak to trendy powdered greens supplements, with prices reflecting the specialized market. The online supermarket reports strong demand for protein-rich staples, health drinks, and supplements.
Adding to the trend, M&S has introduced its "Nutrient Dense" range, while the Co-op is pushing "mini meals." These products are designed to be ideal for those reducing their food intake.
But here's where it gets controversial... While only about 6% of UK adults currently use GLP-1 drugs, analysts suggest their impact on consumer behavior is significantly amplified. This includes a growing focus on high-protein foods and smaller portion sizes.
In recent trading updates, major retailers noted changes in shopping habits. Greggs, for example, observed a shift towards "smaller portions" and healthier choices. Sainsbury's is also responding with more low-calorie and high-protein ready meals. Even Tesco is closely monitoring the trend.
And this is the part most people miss... Despite a 2.5% increase in the value of UK grocery sales, the volume of food and drink sold actually declined by 0.2%. This raises concerns for food and hospitality businesses, as the widespread use of these drugs could potentially impact profits. A study found that households with a GLP-1 user reduced their grocery spend by 5.3% within six months, with higher-income households cutting back by 8.2%.
However, there's a catch: shrinkflation. Can supermarkets successfully market smaller portions without raising eyebrows? There's also the question of whether consumers want products explicitly labeled as "GLP-1 friendly."
Morrisons' "GLP-1 friendly" ready meals, for instance, are the same price as their other diet ranges, but with smaller portions, resulting in a 35% price premium per 100g, according to a fast-moving consumer goods category consultant. M&S's Nutrient Dense ready meals are priced within typical ready meal pack sizes. M&S, Co-op, and Iceland have wisely avoided explicitly mentioning GLP-1 drugs on packaging, recognizing the potential stigma.
One analyst suggests that the M&S range is most likely to succeed, as its target demographic can afford the drugs privately. They also question whether the impact on sales reported by Greggs is more related to consumers cutting back on discretionary food spending due to rising food prices.
Ultimately, in a highly competitive UK grocery market, food market product developers are under pressure to react. The challenge lies in convincing shoppers that these specialized products are a genuine need, rather than just a marketing tactic. Are smaller portions the future, or just another way to repackage what we already have?
What do you think? Are you seeing these changes in your own shopping habits? Do you think these specialized products are a good idea, or just a way for supermarkets to capitalize on a trend? Share your thoughts in the comments below!
